Ptc Therapeutics(NASDAQ) PTCT

PTC Therapeutics makes medicines for people living with rare and serious health disorders. These treatments help children and adults manage complex conditions that affect their muscles and brain. The company sells its products to patients in many different countries around the world.

What is in the Medicine Cabinet?

• Duchenne Muscular Dystrophy: Translarna and Emflaza treat a rare muscle-wasting disease that primarily affects young boys by helping their bodies function better.
• Phenylketonuria Treatments: Sephience is an oral medicine for patients with this metabolic disorder, helping them break down essential amino acids.
• Gene Therapy: Upstaza and Kebilidi provide a one-time treatment for a rare brain disorder that stops children from developing motor control.
• Latin American Rare Disease Portfolio: Tegsedi and Waylivra are commercialized in specific regions to treat rare genetic conditions affecting the nerves and fat metabolism.
• Spinal Muscular Atrophy: Evrysdi is a medicine developed with partners to treat a genetic disease that causes muscle weakness and wasting.

How the Business is Growing

• Entered a major license and collaboration agreement with Novartis in November 2024 to develop and sell a treatment for Huntington's disease.
• Acquired Censa Pharmaceuticals in May 2020 to add the metabolic disease treatment Sephience to its global product pipeline.
• Expanded its gene therapy reach by acquiring Agilis Biotherapeutics in August 2018 to target rare central nervous system disorders.
• Sold its remaining royalty rights for Evrysdi to Royalty Pharma in December 2025 for $240 million in upfront cash.

What Makes PTC Stand Out

PTC operates a global commercial network that delivers specialized rare disease treatments across the United States, Europe, and Latin America. Its scientific platforms focus on splicing and metabolic pathways to discover new ways to treat conditions with no existing options.

The Recent Financial Story

• Revenue fell to $164.7 million in Q4 2025, a 22.7% decrease from $213.2 million in Q4 2024.
• Net loss widened to $135 million in Q4 2025 compared to a loss of $65.9 million in Q4 2024.
• Market capitalization grew to $6.1 billion in Q4 2025, up 75.9% from $3.5 billion in Q4 2024.
• Free cash flow was negative $36.6 million in Q4 2025, staying nearly flat compared to Q4 2024.

The Evolution of PTC

PTC has transitioned from a research-focused firm into a commercial biopharmaceutical company with multiple approved products. Its growth is now driven by expanding its rare disease portfolio through internal discovery and strategic global partnerships.